Aventis Pharma or Rhône-Poulenc Biochimie were not the first to provide the Commission with decisive information on the methylglucamine cartel, as required under point (a) of Section C of the Leniency Notice. Consequently none of the undertakings meet the conditions as set out in Section C.
3.3.7.3. Significant reduction of a fine ("Section D")